Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rethinking neoadjuvant chemotherapy for breast cancer.

× No keyword cloud information.

33 in total

1. Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].

Authors: Mircea Dediu; Christoph Zielinski
Journal: Breast Care (Basel) Date: 2019-08-29 Impact factor: 2.860

2. The neoadjuvant chemotherapy responses and survival rates of patients with different molecular subtypes of breast cancer.

Authors: Hui Zhang; Xiaoyu Zhang; Lijun Jin; Zunyi Wang
Journal: Am J Transl Res Date: 2022-07-15 Impact factor: 3.940

3. Quantitative Ultrasonography as a Tool for the Evaluation of Breast Tumor Response to Neoadjuvant Chemotherapy.

Authors: Hanna Piotrzkowska-Wróblewska; Katarzyna Dobruch-Sobczak; Jerzy Litniewski
Journal: J Ultrason Date: 2022-04-27

4. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century.

Authors: Siddhartha Yadav; Dhauna Karam; Irbaz Bin Riaz; Hao Xie; Urshila Durani; Narjust Duma; Karthik V Giridhar; Tina J Hieken; Judy C Boughey; Robert W Mutter; John R Hawse; Rafael E Jimenez; Fergus J Couch; Roberto A Leon-Ferre; Kathryn J Ruddy
Journal: Cancer Date: 2019-10-07 Impact factor: 6.860

5. Overuse of Neo-adjuvant Chemotherapy for Primary Breast Cancer.

Authors: Nikita Wadhwani; Ismail Jatoi
Journal: Indian J Surg Oncol Date: 2019-10-30

6. The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study.

Authors: Litong Yao; Zhiyuan Pang; Mozhi Wang; Mengshen Wang; Xiangyu Sun; Mingke Cui; Yanfu Zheng; Xinyan Li; Haoran Dong; Qiang Zhang; Yingying Xu
Journal: Cancer Biol Med Date: 2021-10-12 Impact factor: 5.347

10. Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.

Authors: Koichi Kubouchi; Kyosuke Shimada; Takamichi Yokoe; Yutaka Tsutsumi
Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec

Rethinking neoadjuvant chemotherapy for breast cancer.